2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
561
Leukemia
282
Precursor Cell Lymphoblastic Leukemia-Lymphoma
235
Lymphoma
160
Myelodysplastic Syndromes
111
Burkitt Lymphoma
91
Congenital Abnormalities
86
Lymphoma, Non-Hodgkin
85
Leukemia, Monocytic, Acute
84
Leukemia, Myelomonocytic, Acute
82
Lymphoma, Large B-Cell, Diffuse
80
Leukemia, Erythroblastic, Acute
75
Leukemia, Megakaryoblastic, Acute
72
Recurrence
70
Lymphoma, Mantle-Cell
70
Lymphoma, Follicular
49
Hodgkin Disease
44
Leukemia, Myelomonocytic, Chronic
43
Leukemia, Biphenotypic, Acute
43
Lymphoma, Large-Cell, Immunoblastic
37
Blast Crisis
37
Anemia, Refractory, with Excess of Blasts
36
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
35
Leukemia, Lymphocytic, Chronic, B-Cell
33
Myeloproliferative Disorders
30
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
28
Lymphoma, B-Cell, Marginal Zone
24
Leukemia, Myeloid, Chronic-Phase
23
Leukemia, Eosinophilic, Acute
23
Leukemia, Basophilic, Acute
22
Interventions
eltrombopag
3
Thrombopoietin
3
avatrombopag
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Jacobs syndrome
×
Cytarabine
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts